The goal of the Gastrointestinal Malignancies Program (Gl Program) is to unravel the pathogenesis and pathophysiology of Gl cancers, study genefic and environmental risk factors, and design and implement novel strategies for diagnosis, treatment, and prevention. The Gl Program emerged from developing program status in 2003 after it had acquired sufficient organizational, investigative, and clinical depth to be reviewed as a CCSG Program in 2005. At the 2005 CCSG review, the Program received an """"""""Outstanding"""""""" merit score and """"""""Approval [was] recommended with an outstanding level of enthusiasm."""""""" The Program has generated a culture of inter-institutional communication and collaboration that has brought together 83 basic, translational, clinical and population science investigators representing 12 departments of HMS and HSPH, and seven DF/HCC institutions, and has armed these investigators with enabling Cores. In the current budget year, Program members generated $13.7 million (total costs) in peer-reviewed grant support, with $11.5 million in funding from the NCI, and have published 1,272 papers (26% intra-programmatic, 50% interprogrammatic, and 32% inter-institutionai) in the current project period (2006 to 2010). Given the complexity and heterogeneity of gastrointestinal malignancies, the Program has elected to emphasize its efforts on colorectal and pancreatic cancers, two of the four leading causes of cancer-related death in the Unites States.
The Specific Aims of the Program are to: 1) utilize existing and emerging genome-scale and computational technologies to integrate multi-dimensional analysis of the somatic genetic and genomic alterations present in colorectal and pancreatic cancers, applying the ensuing knowledge to define key events that drive tumorigenesis, disease progression and drug response;2) utilize genetic model systems to define genetic lesions that drive colorectal and pancreatic tumorigenesis;3) determine whether polymorphic variation in the aforementioned genes increase risk of these cancers;4) undertake targeted clinical trials utilizing novel endpoint assessment and imaging based upon the findings in Aims 1-3;and 5) determine the effectiveness ofthese interventions by evaluating patient outcomes. During the next project period, there will be a concun'ent intensification of efforts on the other gastrointestinal malignancies, including hepatobililary cancers, esophagogastric cancers and neuroendocrine tumors.

Public Health Relevance

Gastrointestinal cancers are a major contributor to the burden of cancer in the United States. The Gastrointestinal Malignancies Program has brought together laboratory and clinical investigators across seven Harvard-affiliated institutions to work collectively to fundamentally understand the biology of these cancers, determine the key genetic alterations that drive the development and progression of these malignancies and develop new methods of prevention, early detection and treatment for the various Gl cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601446
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,953
Indirect Cost
$60,778
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917

Showing the most recent 10 out of 411 publications